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The death ligand TRAIL (Apo2L) has potential for cancer therapy, since tumour cells are thought to be more sensitive than normal
cells. We investigated whether sensitivity to TRAIL increases during the adenoma to carcinoma transition of colorectal carcinogenesis.
Under the same culture conditions, we compared the extent of TRAIL-induced apoptosis in four premalignant adenoma and three
carcinoma cell lines. Although TRAIL induced some apoptosis in adenoma cultures, the carcinoma cell lines were significantly more
sensitive (Po0.001). This finding was recapitulated in an in vitro model of tumour progression in which conversion of the adenoma
cell line AA/C1 to a tumorigenic phenotype was associated with increased TRAIL sensitivity (Po0.001). Increased TRAIL sensitivity
during colorectal carcinogenesis has been previously attributed to changes in the balance between TRAIL receptors TRAIL-R1 and
-R2 and ‘decoy’ receptors TRAIL-R3 and -R4 during malignant progression. To address this, cell surface receptor expression was
measured by flow cytometry. In summary, during colorectal carcinogenesis, there is a marked increase in sensitivity to TRAIL-induced
apoptosis associated with progression from benign to malignant tumour that could be exploited for colon cancer therapy, but
alterations in cell surface TRAIL receptor expression may not be the primary reason for this change.
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Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL/
Apo2L) mediates rapid apoptosis in cancer cell lines of varied
tissue origin (Wiley et al, 1995; Pitti et al, 1996) and has generated
much interest as a potential therapeutic agent due to its apparent
differential effects on normal and tumour cells (Wang and El-
Deiry, 2003). Tumour necrosis factor-related apoptosis-inducing
ligand interacts with four different membrane-bound receptors,
two with cytoplasmic death domains, TRAIL-R1 (DR4) and
TRAIL-R2 (DR5), and two so-called ‘decoy receptors’ TRAIL-R3
(DcR1) and TRAIL-R4 (DcR2) (Ashkenazi and Dixit, 1998). When
TRAIL binds the receptors R1 and R2, the death signal is
transmitted through their intracellular protein–protein interacting
death domains via cytoplasmic adaptor molecules resulting in an
early activation of caspase-8 (Griffith et al, 1998; MacFarlane et al,
2000a). The activation of the caspase cascade leads, in turn, to
cleavage of intracellular substrates such as poly-(ADP-ribose)
polymerase (PARP) (Lazebnik et al, 1994). However, the death
receptors can also transmit signals for cell survival through NF-kB,
and via caspase-8 can activate JNK and p38 MAP kinase pathways
(Chaudhary et al, 1997; Schneider et al, 1997; Mu ¨hlenbeck et al,
1998; MacFarlane et al, 2000b). TRAIL-R3 and TRAIL-R4 are
unable to transmit the death signal, since TRAIL-R3 does not have
a death domain and TRAIL-R4 has a death domain that is
substantially deleted (French and Tschopp, 1999). However, in
some situations, TRAIL-R4 retains the ability to activate the NF-kB
pathway (Degli-Eposti et al, 1997). Initially, the differential
sensitivity between normal and cancer cells was thought to be
due to the presence of decoy receptors on normal cells (Ashkenazi
and Dixit, 1998; Green, 1998). More recent studies have failed to
find an obvious correlation between decoy receptor expression
and the apoptotic response to TRAIL, with levels of TRAIL-R1
and the caspase-8 inhibitory protein c-FLIP being more likely to
affect the sensitivity of some cells to TRAIL-induced apoptosis
(Kim et al, 2000).
Colorectal cancer cells have been reported to be sensitive to
TRAIL-induced death (Gliniak and Le, 1999; Lacour et al, 2001; Lee
et al, 2001; Ravi et al, 2001). The potential of TRAIL for colorectal
cancer treatment is highlighted by the ability of TRAIL to inhibit
growth of xenografts of several colon carcinoma cell lines in mouse
models and to cooperate with chemotherapeutic agents such as
5-fluorouracil (5-FU), cisplatin, doxorubicin and camptothecin
analogue CPT-11 (Ashkenazi et al, 1999; Gliniak and Le, 1999;
Lacour et al, 2001, 2003; Shimoyama et al, 2002). In the carcinoma
cell line HT29, chemotherapeutic agents, as well as potentiating the
mitochondrial amplification of the caspase cascade, enhance
recruitment of the adapter protein FADD and caspase-8 to the
death-inducing signal complex (DISC) (Lacour et al, 2003).
Although Sheikh et al (1999) reported overexpression of
the decoy receptor TRAIL-R3 mRNA in four out of six colon
cancers, with TRAIL-R3 overexpression conferring relative TRAIL
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sresistance, Koornstra et al (2003) found no significant alterations
in expression of the decoy receptors in colonic tumours compared
to normal colonic epithelium in vivo. Although loss of hetero-
zygosity of TRAIL-R2 has been observed in approximately half of
colorectal carcinomas, mutations of the two TRAIL receptor genes
are rare (Arai et al, 1998). The loss of heterozygosity for TRAIL-R2
is not reflected in the level of protein in the tumours (Koornstra
et al, 2001), and TRAIL-R1 and TRAIL-R2 proteins are over-
expressed in colonic tumours relative to normal colonic mucosa
(Koornstra et al, 2003). However, in colorectal carcinomas,
expression of TRAIL-R1, but not TRAIL-R2, correlates with
disease-free survival (Stra ¨ter et al, 2002a).
Normal colonocytes cultured as intact crypts embedded in
collagen have previously been reported to be relatively resistant to
TRAIL-induced apoptosis compared to colorectal carcinoma cells
(Stra ¨ter et al, 2002b), but it is not known whether the sensitivity to
TRAIL is acquired early or late in colorectal carcinogenesis, since
the response of premalignant adenoma cells to TRAIL has
never been examined. Koornstra et al (2003) showed that,
in vivo, cytoplasmic TRAIL-R1 and -R2 expression was higher in
both adenomas and carcinomas compared to normal colonic
epithelium; however, there were no further changes in expression
of either TRAIL receptors or decoy receptors between adenomas
and carcinomas. From these results, it might be assumed that
the sensitivity to TRAIL is acquired early in colorectal tumo-
rigenesis during the formation of the adenoma, and that this is due
to the changes in TRAIL receptor expression. However, the cell
surface expression of TRAIL receptors in adenoma cells has not
been examined, and this could have an important bearing on
the relative TRAIL sensitivity of colorectal epithelial cells
during tumour progression. In this study, we addressed
whether TRAIL sensitivity increases in association with the
adenoma to carcinoma transition by comparing the response
of four adenoma cell lines and three carcinoma cell lines to
TRAIL under the same culture conditions. This is important
because Larribere et al (2004) have shown that the response to
TRAIL is dependent on culture conditions and that growth factor
signalling through phosphatidyl-inositol-3 kinase and its down-
stream target, Akt, attenuates TRAIL-induced apoptosis of
normal human melanocytes. In addition, we used a model of
tumour progression in which an adenoma cell line had been
transformed to a malignant phenotype in vitro (Williams et al,
1990); this allowed us to measure directly whether TRAIL
sensitivity increased with acquisition of malignancy, again under
the same culture conditions. To assess whether the relative
abundance of TRAIL receptors on the cell surface accounted
for differences in sensitivity to TRAIL-induced apoptosis, we
measured cell surface expression of TRAIL-R1, -R2, -R3 and -R4
by flow cytometry.
MATERIALS AND METHODS
Cell lines and culture conditions
The adenoma cell lines used were AA/C1, RG/C2, AN/C1 and RR/
C1. These cells were capable of growth after trypsinisation to single
cells and are derivatives of the cell lines PC/AA (Paraskeva et al,
1984), S/RG (Paraskeva et al, 1989), S/AN (Paraskeva et al, 1989)
and S/RR (Williams et al, 1992). The carcinoma cell lines used
were HT29 (Fogh and Trempe, 1975), SW620, derived from a
lymph node metastasis (Leibovitz et al, 1976), and KS (Hague et al,
1997), which was derived in our laboratory using the same
techniques as for the adenoma cultures. Whereas the four
adenoma cell lines were anchorage-dependent and did not form
tumours in nude mice (Williams et al, 1990; Hague et al, 1997), the
carcinoma cell lines were anchorage-independent and tumorigenic
after subcutaneous injection in nude mice. The AA/C1/SB/10 cell
line is an in vitro-transformed variant of the AA/C1 adenoma cell
line that is anchorage-independent and forms tumours in nude
mice (Williams et al, 1990).
All of the cell lines used in this study were grown in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco) containing 20% fetal
bovine serum (Gibco, batch selected), glutamine (2mM), insulin
(0.2uml
1), hydrocortisone sodium succinate (1mgml
1),
penicillin (100uml
1) and streptomycin (100mgml
1). Cells
were grown in T25 flasks and were routinely passaged using
trypsin (0.1%) (Difco, West Molesey, Surrey, UK)/EDTA (0.1%)
(AnalaR, BDH).
Preparation of TRAIL and treatment of cells
The TRAIL preparation used was recombinant soluble TRAIL with
N-terminal T7 and His6 tags obtained by nickel affinity purifica-
tion as previously described (MacFarlane et al, 1997). For dose–
response experiments, a stock solution of TRAIL (1mgml
1) was
prepared in EDTA (150mM) and diluted in medium to give final
concentrations of 0.25, 0.5 and 1.0mgml
1. Duplicate or triplicate
flasks were treated with each TRAIL concentration or EDTA only.
Control cultures were treated with the vehicle only.
Identification of apoptosis
As previously demonstrated in these cells (Hague et al, 1993),
apoptosis results in rapid detachment from the flask and the
apoptotic cells float in the medium. Floating cells were collected
at the end of the treatment time and adherent cells were
harvested by trypsinisation. Adherent and floating cells were
quantified using a counting chamber. The extent of apoptotic cell
shedding was calculated as the number of floating cells per
flask divided by the total cell yield (number of adherent plus
floating cells). Adherent and floating cells were examined
separately for apoptotic morphology by acridine orange staining
as described previously (Hague et al, 1993). Unfixed cells
were stained with 5mgml
1 acridine orange in PBS for 10min
and were then viewed by fluorescence microscopy. For each
experiment, the cells shed into the medium were confirmed to be
morphologically apoptotic with condensed chromatin. At least
150 cells were scored per sample. To further demonstrate
that TRAIL induced apoptotic death, adherent and floating cells
were examined separately for DNA laddering as described
previously (Hague et al, 1993). Cleavage of PARP was detected
by Western blot analysis.
SDS–PAGE–Western blotting
Western blotting was carried out used standard techniques and
antibody binding was detected using an enhanced chemilumines-
cence (ECL) detection kit (Amersham, Buckinghamshire, UK)
following the manufacturer’s protocol. To detect BID, two
antibodies were used: a polyclonal BID antibody (1:200) kindly
provided by Dr Xiadong Wang (Howard Hughes Medical Institute,
Texas) and a polyclonal BID antibody (AF860) (1:1000) from R&D
systems. c-FLIP rabbit polyclonal antibody was a gift from Dr D
Nicholson (Merck Frosst, Canada) and was used at 1:1000. Results
were confirmed using a mouse monoclonal antibody, NF-6 (Alexis
Corporation) at 1:1000. XIAP was detected with a mouse
monoclonal antibody used at 1:500 (BD Transduction Labora-
tories). A mouse monoclonal a-tubulin antibody (Sigma, Poole,
Dorset, UK) or a mouse monoclonal a-GAPDH antibody
(Advanced Immunochemical Inc., CA, USA) was used to assess
equal loading of the gels, both at 1:2000. Secondary antibodies
were anti-mouse or anti-rabbit horseradish peroxidase-conjugated
antibodies (Sigma).
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expression
TRAIL-R1, -R2, -R3 and -R4 receptor antibodies (clones M272,
M413, M430 and M444, respectively) were kind gifts from
Immunex Corp. (Seattle, WA, USA) and have been described
previously (Griffith et al, 1999). These antibodies have been
validated for flow cytometric measurement of surface TRAIL
expression (Zhang et al, 2000; MacFarlane et al, 2002). A total of
10
6 trypsinised colon cells (live) were incubated in blocking buffer
(PBS containing 10% normal goat serum) for 30min on ice to
block nonspecific binding. They were then incubated for 1h with
anti-TRAIL receptor antibodies (diluted 1:50) at 41C. After two
washes in PBS and centrifugation for 5min at 400g, the cells were
resuspended in blocking buffer containing goat anti-mouse FITC-
conjugated antibody (F(ab)2 fragment) (DAKO) (1:20 dilution)
and incubated for 1h at 41C. The cells were then washed twice in
cold PBS prior to analysis by flow cytometry (FACScan, Becton
Dickinson). Dead cells were excluded by costaining the cells with
propidium iodide. The propidium iodide-positive cells could then
be gated out.
Statistical analysis
The response of adenomas and carcinomas was compared by a
two-way analysis of variance of TRAIL-induced apoptosis
(malignant potentialTRAIL concentration). For the comparison
of TRAIL sensitivity between the parental adenoma cell line AA/C1
and the transformed adenoma cell line AA/C1/SB/10, a two-way
analysis of variance was conducted (cell lineTRAIL con-
centration). All analyses were conducted using SPSS 10 for
Windows software.
RESULTS
Colorectal cancer cells are more sensitive to TRAIL-
induced apoptosis than premalignant adenoma cells
In this study, we addressed whether there is differential sensitivity
to TRAIL-induced apoptosis between malignant and premalignant
colorectal epithelial cells. Initially, the apoptotic response of four
premalignant, nontumorigenic adenoma cell lines (RG/C2, RR/C1,
AN/C1 and AA/C1) was compared with that of three carcinoma cell
lines (HT29, SW620 and KS) by conducting dose–response
experiments for each cell line. In order to determine the extent
of resistance of the adenoma cells, relatively high concentrations of
TRAIL were used (0.25–1mgml
1). As in our previous studies
quantifying apoptosis in colon cells, we used cell shedding as an
assessment of the extent of apoptosis (Hague et al, 1993). The cells
shed into the medium in response to TRAIL treatment were
confirmed to be apoptotic by acridine orange staining and
examination of the floating cells by fluorescent microscopy for
condensed chromatin, PARP cleavage to its 85kDa form and DNA
laddering (data not shown). Treatment with TRAIL did not induce
necrosis in any of the cell lines even at concentrations up to
2mgml
1. Measurements of the extent of apoptotic cell shedding
after a 16h treatment demonstrated that, although TRAIL induced
apoptosis in the adenoma cell cultures, the carcinoma cell lines
were markedly more sensitive to TRAIL than the adenoma cell
lines (Figure 1). When extensive shedding was obtained over the
16h treatment period, this was reflected in reduced adherent cell
yields (data not shown). The three carcinoma cell lines were
markedly more sensitive than the four adenoma cell lines, a
difference that was highly statistically significant (Po0.001).
To confirm that TRAIL-mediated apoptosis was due to receptor
ligation and not due to nonspecific toxicity of TRAIL, a TRAIL-R2-
Fc chimeric protein, comprised of the TRAIL-R2 extracellular
domain fused to human IgG1 Fc, was used as a soluble receptor
and blocking reagent. TRAIL-R2-Fc completely blocked TRAIL-
induced apoptotic cell shedding in the carcinoma cell line HT29,
confirming that death receptor-mediated apoptosis was respon-
sible for the cell shedding induced by TRAIL treatment (Figure 2A).
Consistent with this, TRAIL treatment resulted in activation of
caspase-8, with cleavage of the proform of 55kDa to 43, 41 and
18kDa fragments (Figure 2B) together with cleavage of the 26kDa
proform of BID to yield its 15kDa fragment (Figure 2C). Cleavage
of caspase-8 and BID was accompanied by reduced levels of the
full-length forms (Figure 2B and C).
The in vitro-transformed adenoma cell line AA/C1/SB/10
is more sensitive to TRAIL-induced apoptosis than the
parental adenoma cell line AA/C1
Since adenoma cells appeared to be more resistant to TRAIL than
carcinoma cells, experiments were conducted to determine more
directly whether TRAIL sensitivity increased in association with
malignant progression by comparing the sensitivity of AA/C1, an
anchorage-dependent, nontumorigenic, adenoma-derived cell line,
and AA/C1/SB/10, an anchorage-independent, tumorigenic deri-
vative of the AA/C1 cell line (Williams et al, 1990). In these
experiments, cell shedding was confirmed to be due to apoptosis
by acridine orange staining for apoptotic morphology and by
detection of PARP cleavage (data not shown). Although the
transformed AA/C1/SB/10 cell line had lower levels of spontaneous
apoptosis than the parental AA/C1 cell line, dose–response
experiments demonstrated that AA/C1/SB/10 was more sensitive
to TRAIL-induced apoptosis than AA/C1 (Po0.001) (Figure 3).
The AA/C1 cells remained relatively resistant with increasing
concentrations of TRAIL (0.25, 0.5 and 1mgml
1). Even 2mgml
1
TRAIL did not induce as much apoptotic cell shedding in AA/C1 as
that induced by 0.25mgml
1 in AA/C1/SB/10 (data not shown).
Therefore, the differential sensitivity between the two cell lines was
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Figure 1 Induction of apoptotic cell shedding by TRAIL in four
colorectal adenoma cell lines (RG/C2, RR/C1, AN/C1 and AA/C1) and
in three carcinoma cell lines (HT29, SW620 and KS). Cells were treated in
exponential growth with either vehicle only or 0.25, 0.5 or 1.0mgml
1
TRAIL for 16h. The floating cells and adherent cells were counted
separately. Floating cells were confirmed as apoptotic by acridine orange
staining for each experiment. The extent of apoptosis was calculated as the
proportion of the total cells in the flask that were floating in the medium.
For each experiment, TRAIL-induced apoptosis is shown as the percentage
of apoptotic cells shed into the medium over and above that in the control
cultures. Data are means7s.e.m. of at least three experiments conducted
either in duplicate or triplicate. The percentages of floating apoptotic cells in
the control cultures were as follows: 12.12% for RG/C2, 3.66% for RR/C1,
1.85% for AN/C1, 3.55% for AA/C1, 1.01% for HT29, 3.56% for SW620
and 3.47% for KS. The mean induced apoptotic cell shedding was
compared between adenoma-derived cell lines and carcinoma-derived cell
lines using a two-way analysis of variance. The difference was highly
statistically significant (Po0.001).
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differential sensitivity was maintained even after 96h exposure to
TRAIL (data not shown). It can be concluded that AA/C1 became
more sensitive to TRAIL-induced apoptosis during malignant
transformation in vitro.
Cell surface receptor expression profiles of adenoma and
carcinoma cells cannot account for their differential
sensitivity to TRAIL
Since it has been reported that there are no differences in total
TRAIL receptor expression between colorectal adenomas and
carcinomas (Koornstra et al, 2003), we addressed whether the
differential sensitivity between nonmalignant and malignant
colonic epithelial cells could be explained by relative cell surface
expression of TRAIL receptors. To do this, flow cytometric
analysis of antibody-labelled nonfixed cells was performed. The
antibodies used to detect TRAIL receptors have been well
characterised for efficient receptor binding by Griffith et al
(1999) and for detection of cell surface TRAIL receptors by flow
cytometry (Zhang et al, 2000; MacFarlane et al, 2002). TRAIL-R1
levels were low and similar in adenoma and carcinoma cell lines
(Table 1). TRAIL-R2 was expressed in all of the eight cell lines and
was the most abundant of the four receptors. AA/C1, which was
relatively resistant to TRAIL, had the highest levels of TRAIL-R2,
whereas KS, which was sensitive to TRAIL-induced apoptosis, had
low levels. TRAIL-R3 was expressed in the adenoma cell lines AN/C1
and AA/C1, and in the transformed adenoma cell line AA/C1/SB/
10, but interestingly, the other five colonic tumour cell lines did
not express cell surface TRAIL-R3. Similarly, only three cell lines
expressed the TRAIL-R4 receptor (at low levels): the carcinoma
cell line HT29, the adenoma cell line AN/C1 and the transformed
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Figure 3 The in vitro-transformed, tumorigenic AA/C1/SB/10 cell line is
more sensitive to TRAIL-induced apoptosis than the adenoma cell line AA/
C1 from which it was derived. Dose response of the adenoma cell line AA/
C1 and the in vitro-transformed adenoma cell line AA/C1/SB/10 showing
the extent of apoptotic cell shedding after a 16h treatment with 0.25, 0.5
and 1mgml
1 TRAIL. Results shown are means7s.e.m. of three
experiments performed in triplicate. Comparing the percentage of
apoptotic cell shedding between AA/C1 and AA/C1/SB/10 by a two-way
analysis of variance revealed a significantly greater extent of apoptosis in
AA/C1/SB/10 (Po0.001).
Table 1 Flow cytometric analysis of TRAIL receptor expression
Adenoma cell lines
Transformed adenoma
Carcinoma cell lines
RG/C2 RR/C1 AN/C1 AA/C1 AA/C1/SB/10 HT29 SW620 KS
CON
a 3.72 5.48 7.22 6.09 3.79 3.37 3.79 2.37
NEG
b 4.28 5.95 7.26 6.61 3.98 3.65 4.05 2.55
TRAIL-R1 5.50 7.49 8.70 7.55 4.84 5.19 5.84 2.81
TRAIL-R2 13.75 25.69 27.14 98.18 27.97 17.01 24.67 4.52
TRAIL-R3 4.10 5.90 9.39 10.60 4.10 3.92 3.91 2.49
TRAIL-R4 4.31 5.80 8.02 6.67 5.54 4.38 4.20 2.48
Values are the mean fluorescent intensity of live (propidium iodide-excluding) cells stained with monoclonal antibodies and detected using an FITC-conjugated mouse secondary
antibody.
aCells incubated without primary or secondary antibody.
bCells incubated with secondary antibody only.
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Figure 2 (A) Apoptosis induced by TRAIL is receptor-mediated and
involves cleavage of caspase-8 and BID. Apoptosis induced by TRAIL in the
HT29 cell line is blocked using TRAIL R2-Fc chimeric protein (R and D
systems, Abingdon, UK) to compete with cellular TRAIL receptors for the
death ligand. Apoptotic cell shedding induced by 0.25mgml
1 TRAIL was
completely blocked by 300mgml
1 TRAIL-R2-Fc. (B) Caspase-8 is cleaved
in HT29 cells in response to TRAIL treatment (16h). Lane 1: adherent
control cells; lane 2: adherent cells treated with 0.125mgml
1 TRAIL; lane
3: adherent cells treated with 0.25mg/ml TRAIL. (C) BID is cleaved in HT29
cells in response to 16h TRAIL treatment. Lane 1: control adherent cells;
lane 2: TRAIL-treated adherent cells (0.25mgml
1); lane 3: control
adherent and floating cells pooled; lane 4: TRAIL-treated adherent and
floating cells pooled.
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TRAIL receptors did not correlate with sensitivity to TRAIL or the
malignant potential of the cell lines. Similarly, the receptor profiles
of the AA/C1 cell line and the transformed adenoma cell line AA/
C1/SB/10 did not explain why the transformed derivative was more
sensitive to TRAIL-induced apoptosis (Figure 4 and Table 1).
The relative resistance of the adenoma cell lines to
TRAIL-induced apoptosis cannot be accounted for by
higher expression of XIAP or c-FLIP
Given the lack of correlation between malignant potential and
TRAIL receptor expression, we further investigated the relative
resistance of adenoma cell lines to TRAIL by examining
intracellular components of the death receptor signalling pathway
that have previously been shown to modulate TRAIL sensitivity.
c-FLIP, an inhibitor of caspase-8 activation, and XIAP, an inhibitor
of active caspases-3 and -9, were expressed in all of the cell lines.
c-FLIPL levels were markedly higher in the transformed adenoma
cell line AA/C1/SB/10 than in the parental adenoma cell line AA/C1
(Figure 5, top panel, compare lanes 4 and 5). Thus, c-FLIP levels
did not appear to correlate with TRAIL sensitivity. Although c-
FLIPS serves to inhibit TRAIL-induced apoptosis in some cell types
(Bin et al, 2002), none of the colorectal tumour cell lines expressed
c-FLIPS. XIAP levels also did not appear to correlate with TRAIL
sensitivity. Although XIAP levels were slightly higher in the
parental adenoma cell line AA/C1 than in AA/C1/SB/10, the
other cell lines had similar expression levels of XIAP (Figure 5,
middle panel).
DISCUSSION
Interest in TRAIL as a potential chemotherapeutic agent stems
from observations suggesting that it may selectively induce
apoptosis in cancer cells while sparing normal cells. Increased
sensitivity to TRAIL during carcinogenesis is not a feature of all
tissues; for example, comparisons of the response of normal and
malignant ovarian cells to TRAIL have shown normal cells to be
sensitive to TRAIL whereas cells from different ovarian carcinomas
varied in their responses (Lane et al, 2004). Normal colonocytes
have previously been reported to be relatively resistant to TRAIL-
induced apoptosis compared to colorectal carcinoma cells: normal
human colonic epithelial cells did not undergo apoptosis in
response to 0.1mgml
1 TRAIL, but COLO205 colon carcinoma
cells were sensitive to this concentration (Stra ¨ter et al, 2002b).
Koornstra et al (2003) reported that colonic tumours over-
expressed the TRAIL receptors TRAIL-R1 and TRAIL-R2 in vivo
relative to normal mucosa, but that overall expression of TRAIL
receptors was not significantly different between adenomas and
carcinomas. On the basis of these observations, one might predict
that the acquisition of TRAIL sensitivity would occur early in
colorectal carcinogenesis and that adenoma cells would be as
sensitive to TRAIL-induced apoptosis as carcinoma cells. However,
it was not known whether there was a difference in TRAIL
sensitivity between adenoma and carcinoma cells and whether
TRAIL receptor expression on the cell surface, rather than
intracellular receptor pools, would correlate with sensitivity to
TRAIL-induced apoptosis. We addressed this hypothesis by
comparing the extent of apoptosis induced by TRAIL in
nonmalignant and malignant colorectal tumour cell lines. We
initially questioned whether TRAIL was able to induce apoptosis of
human colorectal adenoma cells, since this has not been reported
before. The adenoma-derived cell lines did exhibit some apoptosis
in response to TRAIL; however, all four adenoma cell lines, AA/C1,
AN/C1, RR/C1 and RG/C2, were markedly more resistant than the
three carcinoma cell lines HT29, SW620 and KS. The differential
sensitivity between the adenoma and carcinoma cell lines was
highly statistically significant (Po0.001). Furthermore, we used an
in vitro model of colorectal carcinogenesis to demonstrate that the
adenoma cell line AA/C1 became more sensitive to TRAIL after
in vitro transformation to a malignant phenotype (Po0.001). Our
studies provide direct evidence for increasing TRAIL sensitivity
during colorectal carcinogenesis during the adenoma to carcinoma
transition. They also show that the increased sensitivity to TRAIL
can be recapitulated in vitro, and therefore in vivo selection
pressures are not necessarily required for the acquisition of TRAIL
sensitivity. The increased TRAIL sensitivity may relate to
increasing growth rate or growth autonomy, or to the attainment
of anchorage independence.
In normal colonic epithelium, apoptosis is primarily at the crypt
lumen (Brodie et al, 2004), and for the most part at the top of the
crypts (Hall et al, 1994). In early adenomas, there is apoptosis close
to the basement membrane, particularly at crypt branching points
(Brodie et al, 2004), whereas crypt lumen apoptosis is a feature of
larger adenomas, high-grade dysplasia and adenocarcinomas. It is
unknown to what extent TRAIL responsiveness contributes to the
changing patterns of apoptosis in human colorectal tumours.
However, the contribution of TRAIL-R2 to colorectal tumour
Con
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TR3
TR2
TR1
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98.2
7.5
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TR4
TR3
TR2
TR1
5.5
4.1
28.0
4.8
4.0
AA/C1/SB/10 AA/C1
Figure 4 Cell surface receptor expression in the adenoma cell line AA/
C1 (premalignant) and the in vitro-transformed derivative AA/C1/SB/10
(malignant). Cell surface expression of the four TRAIL receptors was
detected by single-colour flow cytometric analysis of live (propidium
iodide-excluding) cells stained with monoclonal antibodies and detected
using a FITC-conjugated anti-mouse secondary antibody (See legend to
Table 1, values shown correspond to Mean Fluorescence Intensity).
Control cells were incubated with secondary antibody only. The
experiment was repeated with similar results.
GAPDH
c-FLIP
XIAP
∗
c-FLIPL
1      2      3      4      5      6       7      8
∗
Figure 5 The relative resistance of the adenoma cell lines to TRAIL-
induced apoptosis cannot be accounted for by higher expression of XIAP
or c-FLIP. c-FLIP and XIAP expression in the four adenoma cell lines, the
transformed adenoma cell line and the three carcinoma cell lines is shown.
Lane 1: RG/C2; lane 2: RR/C1; lane 3: AN/C1; lane 4: AA/C1; lane 5: AA/
C1/SB/10; lane 6: HT29; lane 7: SW620; lane 8: KS. Bands corresponding to
the full-length proteins are arrowed. The asterisks denote nonspecific
bands. Since XIAP is of similar size to a-tubulin, GAPDH was used as a
loading control for this blot.
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by Wang and El-Deiry (2004) using stable human colon cancer cell
lines in which the function of TRAIL-R2 was ablated using
inducible RNA interference in a mouse xenograft model. Inducible
silencing of TRAIL-R2 in vivo accelerated growth of biolumines-
cent tumour xenografts and conferred resistance to the chemo-
therapeutic agent 5-FU. Stra ¨ter et al (2002a) found that in normal
colonic epithelium, TRAIL and TRAIL-R2 were expressed primar-
ily in the surface epithelium, whereas TRAIL-R1 and TRAIL-R4
were detected all along the crypt axis. In adenomas, this expression
pattern was mostly retained, although some adenomas also
expressed abnormally high levels of TRAIL-R3. In carcinomas,
the expression of TRAIL and TRAIL receptors was much more
variable, but TRAIL-R1 expression was significantly associated
with disease-free survival. Koornstra et al (2003) also reported
overall expression of TRAIL receptors, which have a large
cytoplasmic component, to be similar in adenoma and carcinoma
cells; therefore, immunohistochemical studies have not revealed a
mechanism for the differences in TRAIL sensitivity between the
adenoma and carcinoma cells. We therefore examined the cell
surface expression of the four TRAIL receptors by flow cytometry.
The importance of examining cell surface expression of TRAIL
receptors has been highlighted recently by Jin et al (2004), who
showed that TRAIL-resistant variants of the colon carcinoma cell
line SW480 had reduced cell surface expression of TRAIL-R1
compared to the parental cell line, although total protein
expression remained unchanged. However, it is interesting that
in our study the cell surface expression of the four TRAIL
receptors did not correlate with the increased sensitivity to TRAIL
that is associated with malignancy. Importantly, this indicates that
the increased sensitivity to TRAIL may instead be due to
alterations in intracellular signalling. In this regard, it is worth
noting that we found no correlation between the expression of
c-FLIP or XIAP, or of Bcl-2 family members Bcl-2, Bcl-xL, Bax or
Bak to explain the differential sensitivity (data not shown).
Furthermore, TRAIL-induced NF-kB activity did not correlate with
malignant potential or sensitivity to TRAIL-induced apoptosis
(data not shown).
In summary, using an in vitro model of colorectal tumour
progression, we have demonstrated for the first time that
colorectal adenoma cells are more resistant to TRAIL-induced
apoptosis than carcinoma cells and that TRAIL sensitivity
increases during the conversion of an adenoma cell line to a
malignant phenotype. Importantly, since the adenoma cultures are
grown under the same culture conditions as the carcinoma
cultures, this cannot be attributed to differences in survival factors
or medium composition. The results are important for the
potential application of TRAIL as a treatment for colorectal cancer
because of the current focus on the mechanisms of TRAIL
resistance in colorectal tumours – it will be important to define the
‘window’ of TRAIL sensitivity. Although the mechanism for the
differential sensitivity of benign and malignant cells to TRAIL
remains elusive, our data indicate that death receptor expression
alone cannot explain why cells become sensitive to TRAIL on
acquisition of the malignant phenotype. Therefore, in addition to
defining mechanisms by which resistant variants may subse-
quently arise after prolonged TRAIL treatment, further investiga-
tions are also needed to define the mechanisms by which colorectal
carcinoma cells become sensitive to TRAIL and what selective
advantage of tumour cells has given rise to this sensitivity.
Together, these investigations will assist in the optimisation of
TRAIL for therapeutic use.
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